AI Science Tracker

Iambic Therapeutics

1 discovery from 2026

Discoveries

AI-designed brain-penetrant HER2 inhibitor IAM1363 shows durable responses in Phase 1/1b

Iambic reported updated results from an open-label Phase 1/1b study of its AI-designed HER2 inhibitor IAM1363. At the August 31, 2026 cutoff, 122 participants had received treatment across four study parts; the company reported antitumor and intracranial responses and that more than half of participants treated at 960 mg remained on treatment. This summary is limited to the company release of October 26, describing an October 23 conference poster. These uncontrolled early results do not establish comparative efficacy.

Technology: Iambic molecular superintelligence platform

Publication: Announcement only · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Announcement only
  • Test type: direct test
  • Tested: Company-reported safety and preliminary response outcomes from an ongoing open-label Phase 1/1b trial.
  • Still unknown: Source checking does not establish independent confirmation. Review date: 2026-11-15.
  • AI role: The molecule was 'designed using Iambic's molecular superintelligence platform' and progressed to clinic in about two years, as stated by the company.

Evidence sources: https://ir.iambic.ai/news-releases/news-release-details/iambic-presents-updated-iam1363-clinical-data-esmo-2026-showing

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: press release. Paper: not linked in this catalog; this does not mean no paper exists.

Review scope and date are not recorded; source checked does not establish full-text review.

Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Open the interactive profile for the timeline, or browse all organizations and model families.